Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05231122 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv24
  2. Primary and study completion pushed from Dec 30, 2026 to Mar 15, 2027v23
  3. Eligibility criteria shortened, about 11 wordsv22
  4. Site contacts updated at 1 of 2 sitesv21
  5. Eligibility criteria expanded, about 123 wordsv20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 1 of 2 sitesv19
  2. Eligibility criteria shortened, about 47 wordsv18
  3. Eligibility criteria expanded, about 7 words
    • Collaborators revised (3)
    v17
  4. Start date changed from estimate of Mar 1, 2024 to Mar 12, 2024v16
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 30, 2023 to Mar 1, 2024
    • Site details revised at 2 of 2 sites
    v15
  6. Start date: Oct 30, 2023 to Dec 30, 2023
    • Primary and study completion dates: Oct 30, 2026 to Dec 30, 2026
    v14
  7. Start date: Sep 30, 2023 to Oct 30, 2023
    • Primary and study completion dates: Jun 30, 2026 to Oct 30, 2026
    v13
  8. Start date: Jun 30, 2023 to Sep 30, 2023v12
  9. Start date: May 15, 2023 to Jun 30, 2023
    • Primary and study completion dates: May 15, 2026 to Jun 30, 2026
    v11
  10. Eligibility criteria expanded, about 111 words
    • Collaborators: 1 to 3
    v10
  11. Eligibility criteria expanded, about 6 wordsv9
  12. Start date: Mar 15, 2023 to May 15, 2023
    • Primary and study completion dates: Jan 15, 2026 to May 15, 2026
    v8
  13. Start date: Jan 15, 2023 to Mar 15, 2023v7
  14. Start date: Nov 30, 2022 to Jan 15, 2023
    • Primary and study completion dates: Nov 30, 2025 to Jan 15, 2026
    v6
  15. Start date: Aug 30, 2022 to Nov 30, 2022
    • Primary and study completion dates: Aug 30, 2025 to Nov 30, 2025
    v5
  16. Start date: Jul 30, 2022 to Aug 30, 2022
    • Primary and study completion dates: Jul 30, 2025 to Aug 30, 2025
    v4
  17. Start date: Apr 30, 2022 to Jul 30, 2022
    • Primary and study completion dates: Apr 30, 2025 to Jul 30, 2025
    v3
  18. Start date: Feb 15, 2022 to Apr 30, 2022
    • Primary and study completion dates: Feb 15, 2025 to Apr 30, 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.
Trial Details
NCT Number NCT05231122
Lead Sponsor Roswell Park Cancer Institute
Collaborators: Merck Sharp & Dohme LLC, Celldex Therapeutics, United States Department of Defense
Conditions
(from sponsor)		 Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma +7 more
Related terms Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov